Onset: 30–60 min on empty stomach; up to 90 min with food. Peak: 1–2 hours. Duration: 3–5 hours per dose at 50–100 mg; 4–6 hours at 100–200 mg. The short t½ (1–2 h) means effect tapers off relatively quickly; this is why TID dosing is standard for sustained anxiety/cerebrovascular use.

Characteristic effects at 100–300 mg:

• Mild anxiolysis — described as a "settling" or "smoothing" of low-grade anxiety rather than the dampening effect of benzos or the deeper trance of phenibut. Most users notice a subtle floor-raise on stress tolerance rather than a dramatic shift.
• Non-sedating — this is the defining feature. Unlike phenibut (drowsy at higher doses), benzodiazepines (cognitive blunting), or even high-dose theanine (slight slowing), picamilon's niacin component appears to counterbalance the GABA-driven slow-down.
• Mild cognitive lift — clearer thinking, mild motivation increase, better task initiation. Plausibly the niacin → cerebral blood flow mechanism. Not a focus tool like modafinil; more "removing the friction of low-grade anxiety from cognition" than additive enhancement.
• Smoother social context — confidence in conversation, lower self-monitoring noise. Consistent with mild GABA-A modulation.
• Possible mild vasodilatory warmth — facial warmth, slight skin redness in some users (especially at 200+ mg). This is the niacin component. Not the full niacin "flush" most of the time, but a subset of users get it.

Variability: Moderate. Approximately 30–40% of trial users report no perceptible effect; 50–60% report a "subtle but real" effect; a small minority report strong response. This is a milder compound than phenibut, tianeptine, or benzodiazepines, and the subjective signal can be lost beneath baseline noise for low-anxiety individuals or those expecting a more dramatic shift.

Compared to alternatives:

• vs. theanine 200 mg: Picamilon is mildly more potent for anxiolysis, with a similar non-sedating profile. Theanine has stronger glutamate/dopamine modulation; picamilon has more direct GABA-A recruitment.
• vs. propranolol 20–40 mg: Picamilon hits cognitive/limbic anxiety; propranolol hits peripheral physical symptoms (heart, tremor). Different mechanism, complementary.
• vs. phenibut: Picamilon is much milder, much shorter-acting, and lacks phenibut's GABA-B dominance + dependence/withdrawal profile. Picamilon is what phenibut wishes it were if dependence weren't a problem.
• vs. tianeptine: Both occupy the "atypical mild mood-stabilizer" niche, but tianeptine has the µ-opioid issue and dependence risk; picamilon has neither.
• vs. benzodiazepines: Far milder, no dependence, no cognitive blunting, no sedation, no addiction profile.

• Tolerance buildup: Minimal-to-none in available literature. Russian protocols use 1–2 month continuous courses without documented tolerance issues. PRN users report consistent effect across months/years of intermittent use.
• Recommended cycle: None mandatory. Russian protocols are course-based (1–2 months on, then break) primarily for indication-specific reasons, not tolerance. PRN use is open-ended.
• Reset protocol if needed: N/A. If subjective effect plateaus, more likely a placebo-floor issue or low brain-esterase capacity than tolerance.
• Critical: no withdrawal syndrome at typical doses. This is a key safety/usability differentiator vs. phenibut, benzodiazepines, z-drugs, and tianeptine.

Synergistic with

• l-theanine: Both are mild non-sedating anxiolytics with different mechanisms (theanine: glutamate/dopamine + alpha-wave EEG modulation; picamilon: GABA-A direct). Stack covers both glutamatergic over-excitation and GABA insufficiency. 200 mg theanine + 50–100 mg picamilon is a clean low-anxiety daytime stack.
• propranolol: Picamilon hits cognitive/limbic anxiety; propranolol hits the peripheral somatic axis (heart rate, tremor). For high-stakes performance anxiety (public speaking, exam, important meeting), 20 mg propranolol + 100 mg picamilon 60 min prior is mechanistically complete coverage. Watch combined hypotension — start each separately first.
• taurine: Mild GABA-A agonist itself (extrasynaptic δ-subunit). Plausibly additive at the GABA side. No documented conflict; reasonable daytime stress-day stack.
• agmatine: No mechanistic conflict. Imidazoline/I1/I2 + alpha-2 vs. GABA-A + niacin — different receptor families. Both mild calm tools that can stack.
• modafinil: Picamilon's anxiolytic component can offset modafinil's mild over-arousal/anxiety in users sensitive to it. Stack is daily-safe with no documented interaction.
• magnesium glycinate / threonate: Mg is the physiological NMDA gatekeeper; picamilon adds GABA-A direct stimulation. Excellent safety overlap with V4 magnesium (already in Dylan's stack).
• rhodiola: Stress-modulation complement (rhodiola: HPA-axis + serotonergic; picamilon: GABA + cerebral vascular). Both already separately or scheduled in Dylan's stack.

Avoid stacking with

• Phenibut: Both are GABA-pathway compounds. Phenibut is far more potent (GABA-B agonist + α2δ binder) and stacking with picamilon would mostly amplify the phenibut effect with extra GABA-A coverage. Not dangerous per se, but defeats the purpose — phenibut is the bigger concern, picamilon is the milder tool. Don't stack both in the same window.
• Benzodiazepines (alprazolam, clonazepam, diazepam, lorazepam, etc.): Additive GABA-A modulation. Unnecessary stacking; benzos already saturate the relevant receptor. Picamilon's addition adds no extra clinical benefit but adds CNS depression risk. Avoid.
• Z-drugs (zolpidem, eszopiclone, zaleplon): Same logic as benzos — additive GABA-A. Avoid.
• Barbiturates: Russian label specifically notes picamilon reduces barbiturate duration; this is an interaction (not additive depression but pharmacokinetic interference). Either way, don't combine.
• Alcohol: Additive CNS depression at high alcohol doses. At low alcohol doses (<2 drinks) likely not clinically significant. Dylan is zero-alcohol baseline so this is non-applicable.
• Tianeptine: Both atypical mild mood-modulators; stacking adds no clear benefit and combines two niche compounds with different risk profiles. No documented conflict but no rationale either.
• High-dose niacin (≥500 mg) or niacin-rich pre-workouts: Additive flushing + hepatotoxicity risk. Picamilon already provides niacin in the metabolite pool; adding more compounds the niacin-side effect.
• Strong antihypertensives (clonidine, prazosin, beta-blockers): Additive hypotension. Propranolol stacking is OK for short-duration performance use but flag for chronic combinations.

Neutral / safe co-administration

Modafinil, bromantane, semax, selank, citicoline, NAC, fish oil/DHA, phosphatidylserine, curcumin, rhodiola, theanine, taurine, glycine, tryptophan, D3+K2, beta-alanine, vitamin C, creatine, magnesium (any form), apigenin, ALCAR, astaxanthin. Compatible with full V4 stack.

• CYP enzymes: Picamilon and its metabolites are not significant CYP substrates or inducers. No documented CYP-mediated drug interactions. No interaction with hormonal contraceptives.
• Renal clearance overlap: Picamilon is renally cleared. Combining with other renally cleared drugs (lithium, metformin, NSAIDs) is theoretically additive at the renal handling level, but no documented clinical interaction.
• Barbiturates: Russian product label specifies picamilon reduces duration of action. Mechanism unclear (possibly CYP induction, possibly receptor competition). Either way, don't co-administer with phenobarbital or surgical barbiturates without anesthesia awareness.
• Narcotic analgesics: Russian label specifies enhanced effect. Mechanism is plausibly additive CNS depression + GABA-opioid synergy. Caution if Dylan ever needs surgical opioids — flag picamilon use to anesthesia.
• Antihypertensives: Additive hypotension via niacin-mediated vasodilation. Monitor BP if combined.
• Statins: Theoretical concern — niacin + statins has the rhabdomyolysis interaction signal in chronic high-dose niacin therapy. Picamilon's niacin contribution at therapeutic doses is far below pharmacologic niacin therapy levels (the entire 200 mg picamilon dose contains <100 mg niacin equivalent post-hydrolysis), so this is theoretical rather than clinically demonstrated. Worth noting if Dylan ever lands on statin therapy.

Minimal data. Picamilon's pharmacology depends on three steps: BBB transit (passive, lipophilicity-driven), brain esterase hydrolysis, and downstream GABA-A / niacin-receptor (HCAR2/GPR109A) signaling.

Plausible polymorphism angles (speculative, no clinical correlation studied):

• GABRA2/GABRA1/GABRG2 variants — affect GABA-A receptor subunit composition and benzodiazepine response. May affect picamilon's GABA-side response. No clinical study.
• HCAR2 / GPR109A variants — affect niacin flush severity and downstream PGD2 signaling. May affect both flushing risk and cerebrovascular response. No clinical study.
• Brain esterase capacity — picamilon's effect depends on hydrolysis rate. Inter-individual variation in CNS esterase activity is real but uncharacterized at the polymorphism level for picamilon specifically. The clinical relevance is the ~30–40% non-responder rate in Western anecdotal reports.
• CYP2D6 / CYP3A4 — irrelevant; picamilon is not a CYP substrate.

For Dylan (23andMe results pending June 2026): No actionable pharmacogenomic flags. If 23andMe raw data shows GABRA2 variants (rs279858, rs279826) commonly associated with anxiety phenotype, picamilon may be more or less effective — but this is research-grade speculation, not clinical guidance. Try a 2–3 dose PRN trial to determine response empirically rather than predict from genotype.

Cost estimate for Dylan PRN use: $10–15/month for a 50 mg × 60 pack at 1–2 doses per stress day, 10–15 stress days/month. Annual: $120–180. Negligible compared to V4 ($159/mo) or V5 ($400/mo). One pack lasts 1–3 months at PRN frequency.

Recommendation for Dylan: Order one 50 mg × 60 pack from RUPharma alongside the existing V5 Russian-compound order (Bromantane, Semax, Selank, Adamax, Cerebrolysin, Phenotropil, Picamilon — all from same vendor). $10 incremental cost. Treat as PRN tool.

FDA legal status reminder: Picamilon is an unapproved drug in the US. Personal-use import from Russian pharmacy is in legal gray territory — typically tolerated at small quantities for personal use under FDA's personal-importation policy, but technically subject to seizure. Risk profile is similar to modafinil import: low-probability event, generally not prosecuted.

• Baseline (before starting): Resting BP (especially if hypotension-prone). Resting heart rate. Creatinine + BUN (renal function — contraindicated in chronic renal failure). Liver panel (ALT/AST — niacin-component hepatotoxicity baseline). Subjective anxiety VAS or similar self-report scale.
• During use (PRN): Symptom journal — note dose, context, subjective effect, side effects (flushing, dizziness, headache). After 5–10 doses, evaluate: is there a real signal vs placebo expectation?
• During use (continuous course, e.g., 1-2 month protocol): BP weekly first 2 weeks, then monthly. Subjective tracking. ALT/AST at baseline + 1 month if extended use beyond 4–6 weeks at high doses.
• Post-cycle (if cycled): N/A. No rebound expected. No withdrawal risk.